{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:33:19Z","timestamp":1790137999199,"version":"4.0.1"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Developing an HIV-1 vaccine has been hampered by the inability of immunogens to induce broadly neutralizing Abs (BnAbs) that protect against infection. Previously, we used knockin (KI) mice expressing a prototypical gp41-specific BnAb, 2F5, to demonstrate that immunological tolerance triggered by self-reactivity of the 2F5 H chain impedes BnAb induction. In this study, we generate KI models expressing H chains from two other HIV-1 Abs, 4E10 (another self-\/polyreactive, anti-gp41 BnAb) and 48d (an anti-CD4 inducible, nonpolyreactive Ab), and find a similar developmental blockade consistent with central B cell deletion in 4E10, but not in 48d VH KI mice. Furthermore, in KI strains expressing the complete 2F5 and 4E10 Abs as BCRs, we find that residual splenic B cells arrest at distinct developmental stages, yet exhibit uniformly low BCR densities, elevated basal activation, and profoundly muted responses to BCR ligation and, when captured as hybridoma mAb lines, maintain their dual (gp41\/lipid) affinities and capacities to neutralize HIV-1, establishing a key role for anergy in suppressing residual 2F5- or 4E10-expressing B cells. Importantly, serum IgGs from naive 2F5 and 4E10 KI strains selectively eliminate gp41 and lipid binding, respectively, suggesting B cells expressing 2F5 or 4E10 as BCRs exhibit specificity for a distinct spectrum of host Ags, including selective interactions by 2F5 BCR+ B cells (i.e., and not 4E10 BCR+ B cells) with those mimicked by its gp41 neutralization epitope.<\/jats:p>","DOI":"10.4049\/jimmunol.1300770","type":"journal-article","created":{"date-parts":[[2013,7,4]],"date-time":"2013-07-04T08:25:30Z","timestamp":1372926330000},"page":"1260-1275","source":"Crossref","is-referenced-by-count":87,"title":["Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10"],"prefix":"10.1093","volume":"191","author":[{"given":"Yao","family":"Chen","sequence":"first","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, NC 27710"},{"name":"Department of Medicine, Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, NC 27710"},{"name":"Department of Medicine, Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan-Ki","family":"Hwang","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, NC 27710"},{"name":"Department of Medicine, Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary","family":"Bouton-Verville","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, NC 27710"},{"name":"Department of Medicine, Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Mao","family":"Xia","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, NC 27710"},{"name":"Department of Medicine, Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Newman","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, NC 27710"},{"name":"Department of Medicine, Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Bin","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Taconic Biosciences , Cranbury, NJ 08512"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barton F","family":"Haynes","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, NC 27710"},{"name":"Department of Medicine, Duke University Medical Center , Durham, NC 27710"},{"name":"Department of Immunology, Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Verkoczy","sequence":"additional","affiliation":[{"name":"Duke Human Vaccine Institute, Duke University Medical Center , Durham, NC 27710"},{"name":"Department of Medicine, Duke University Medical Center , Durham, NC 27710"},{"name":"Department of Pathology, Duke University Medical Center , Durham, NC 27710"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,8,1]]},"reference":[{"key":"2025032405151171400_r1","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2010.09.011","article-title":"Induction of immunity to human immunodeficiency virus type-1 by vaccination","volume":"33","author":"McElrath","year":"2010","journal-title":"Immunity"},{"key":"2025032405151171400_r2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","article-title":"Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies","volume":"6","author":"Mascola","year":"2000","journal-title":"Nat. Med."},{"key":"2025032405151171400_r3","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nm.1974","article-title":"Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques","volume":"15","author":"Hessell","year":"2009","journal-title":"Nat. Med."},{"key":"2025032405151171400_r4","doi-asserted-by":"crossref","first-page":"e1000433","DOI":"10.1371\/journal.ppat.1000433","article-title":"Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers","volume":"5","author":"Hessell","year":"2009","journal-title":"PLoS Pathog."},{"key":"2025032405151171400_r5","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1128\/JVI.01272-09","article-title":"Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L","volume":"84","author":"Hessell","year":"2010","journal-title":"J. Virol."},{"key":"2025032405151171400_r6","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nature10660","article-title":"Antibody-based protection against HIV infection by vectored immunoprophylaxis","volume":"481","author":"Balazs","year":"2012","journal-title":"Nature"},{"key":"2025032405151171400_r7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nm1244","article-title":"Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies","volume":"11","author":"Trkola","year":"2005","journal-title":"Nat. Med."},{"key":"2025032405151171400_r8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nri2674","article-title":"The immune response during acute HIV-1 infection: clues for vaccine development","volume":"10","author":"McMichael","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"2025032405151171400_r9","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nbt.2197","article-title":"B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study","volume":"30","author":"Haynes","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"2025032405151171400_r10","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.coi.2011.04.003","article-title":"Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies","volume":"23","author":"Verkoczy","year":"2011","journal-title":"Curr. Opin. Immunol."},{"key":"2025032405151171400_r11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1586\/14760584.5.4.579","article-title":"Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates","volume":"5","author":"Haynes","year":"2006","journal-title":"Expert Rev. Vaccines"},{"key":"2025032405151171400_r12","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1126\/science.280.5371.1884","article-title":"The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens","volume":"280","author":"Wyatt","year":"1998","journal-title":"Science"},{"key":"2025032405151171400_r13","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","article-title":"Rapid evolution of the neutralizing antibody response to HIV type 1 infection","volume":"100","author":"Richman","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032405151171400_r14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/nature01188","article-title":"HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites","volume":"420","author":"Kwong","year":"2002","journal-title":"Nature"},{"key":"2025032405151171400_r15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","article-title":"Antibody neutralization and escape by HIV-1","volume":"422","author":"Wei","year":"2003","journal-title":"Nature"},{"key":"2025032405151171400_r16","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.1128\/JVI.77.19.10557-10565.2003","article-title":"Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1","volume":"77","author":"Labrijn","year":"2003","journal-title":"J. Virol."},{"key":"2025032405151171400_r17","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1073\/pnas.0800255105","article-title":"A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies","volume":"105","author":"Frey","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032405151171400_r18","doi-asserted-by":"crossref","first-page":"5637","DOI":"10.1128\/JVI.00105-10","article-title":"Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization","volume":"84","author":"Binley","year":"2010","journal-title":"J. Virol."},{"key":"2025032405151171400_r19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/COH.0b013e32832e6184","article-title":"Challenges for structure-based HIV vaccine design","volume":"4","author":"Schief","year":"2009","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2025032405151171400_r20","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nm.1949","article-title":"Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?","volume":"15","author":"Stamatatos","year":"2009","journal-title":"Nat. Med."},{"key":"2025032405151171400_r21","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.tim.2012.08.011","article-title":"HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design","volume":"20","author":"Bonsignori","year":"2012","journal-title":"Trends Microbiol."},{"key":"2025032405151171400_r22","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3233\/HAB-2005-143-402","article-title":"Antibody polyspecificity and neutralization of HIV-1: a hypothesis","volume":"14","author":"Haynes","year":"2005","journal-title":"Hum. Antibodies"},{"key":"2025032405151171400_r23","doi-asserted-by":"crossref","first-page":"6642","DOI":"10.1128\/jvi.67.11.6642-6647.1993","article-title":"A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1","volume":"67","author":"Muster","year":"1993","journal-title":"J. Virol."},{"key":"2025032405151171400_r24","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1089\/08892220152741450","article-title":"A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1","volume":"17","author":"Stiegler","year":"2001","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"2025032405151171400_r25","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1126\/science.1111781","article-title":"Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies","volume":"308","author":"Haynes","year":"2005","journal-title":"Science"},{"key":"2025032405151171400_r26","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/337562a0","article-title":"Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes","volume":"337","author":"Nemazee","year":"1989","journal-title":"Nature"},{"key":"2025032405151171400_r27","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/349331a0","article-title":"Expression of anti-DNA immunoglobulin transgenes in non-autoimmune mice","volume":"349","author":"Erikson","year":"1991","journal-title":"Nature"},{"key":"2025032405151171400_r28","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev.iy.10.040192.002421","article-title":"Transgenic mice and analysis of B-cell tolerance","volume":"10","author":"Goodnow","year":"1992","journal-title":"Annu. Rev. Immunol."},{"key":"2025032405151171400_r29","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1084\/jem.177.4.1009","article-title":"Receptor editing in self-reactive bone marrow B cells","volume":"177","author":"Tiegs","year":"1993","journal-title":"J. Exp. Med."},{"key":"2025032405151171400_r30","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1084\/jem.177.4.999","article-title":"Receptor editing: an approach by autoreactive B cells to escape tolerance","volume":"177","author":"Gay","year":"1993","journal-title":"J. Exp. Med."},{"key":"2025032405151171400_r31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1073\/pnas.0912914107","article-title":"Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance","volume":"107","author":"Verkoczy","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032405151171400_r32","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.4049\/jimmunol.1101633","article-title":"Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controls","volume":"187","author":"Verkoczy","year":"2011","journal-title":"J. Immunol."},{"key":"2025032405151171400_r33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nri2133","article-title":"B-cell anergy: from transgenic models to naturally occurring anergic B cells?","volume":"7","author":"Cambier","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"2025032405151171400_r34","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/353765a0","article-title":"Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens","volume":"353","author":"Hartley","year":"1991","journal-title":"Nature"},{"key":"2025032405151171400_r35","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/373252a0","article-title":"The site and stage of anti-DNA B-cell deletion","volume":"373","author":"Chen","year":"1995","journal-title":"Nature"},{"key":"2025032405151171400_r36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1128\/MMBR.00020-07","article-title":"The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design","volume":"72","author":"Montero","year":"2008","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"2025032405151171400_r37","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1128\/JVI.78.6.3155-3161.2004","article-title":"The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5","volume":"78","author":"Zwick","year":"2004","journal-title":"J. Virol."},{"key":"2025032405151171400_r38","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1084\/jem.20121977","article-title":"Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies","volume":"210","author":"Yang","year":"2013","journal-title":"J. Exp. Med."},{"key":"2025032405151171400_r39","doi-asserted-by":"crossref","first-page":"e7215","DOI":"10.1371\/journal.pone.0007215","article-title":"Functional, non-clonal IgMa-restricted B cell receptor interactions with the HIV-1 envelope gp41 membrane proximal external region","volume":"4","author":"Verkoczy","year":"2009","journal-title":"PLoS ONE"},{"key":"2025032405151171400_r40","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jim.2009.08.009","article-title":"Cloning and expression of murine Ig genes from single B cells","volume":"350","author":"Tiller","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"2025032405151171400_r41","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1128\/jvi.67.7.3978-3988.1993","article-title":"Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding","volume":"67","author":"Thali","year":"1993","journal-title":"J. Virol."},{"key":"2025032405151171400_r42","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.4049\/jimmunol.177.5.2749","article-title":"B-1 B cell development","volume":"177","author":"Hardy","year":"2006","journal-title":"J. Immunol."},{"key":"2025032405151171400_r43","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1084\/jem.20011453","article-title":"Autoreactive B cells in the marginal zone that express dual receptors","volume":"195","author":"Li","year":"2002","journal-title":"J. Exp. Med."},{"key":"2025032405151171400_r44","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/334676a0","article-title":"Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice","volume":"334","author":"Goodnow","year":"1988","journal-title":"Nature"},{"key":"2025032405151171400_r45","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/352532a0","article-title":"Breakdown of self-tolerance in anergic B lymphocytes","volume":"352","author":"Goodnow","year":"1991","journal-title":"Nature"},{"key":"2025032405151171400_r46","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.immuni.2006.10.017","article-title":"Identification of anergic B cells within a wild-type repertoire","volume":"25","author":"Merrell","year":"2006","journal-title":"Immunity"},{"key":"2025032405151171400_r47","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/intimm\/9.11.1615","article-title":"Persistence of functionally compromised anti-double-stranded DNA B cells in the periphery of non-autoimmune mice","volume":"9","author":"Roark","year":"1997","journal-title":"Int. Immunol."},{"key":"2025032405151171400_r48","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.4049\/jimmunol.159.6.2633","article-title":"Characterization of anti-single-stranded DNA B cells in a non-autoimmune background","volume":"159","author":"Nguyen","year":"1997","journal-title":"J. Immunol."},{"key":"2025032405151171400_r49","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.4049\/jimmunol.166.5.3194","article-title":"Anergy and not clonal ignorance determines the fate of B cells that recognize a physiological autoantigen","volume":"166","author":"Rojas","year":"2001","journal-title":"J. Immunol."},{"key":"2025032405151171400_r50","doi-asserted-by":"crossref","first-page":"790","DOI":"10.4049\/jimmunol.176.2.790","article-title":"Early preplasma cells define a tolerance checkpoint for autoreactive B cells","volume":"176","author":"Culton","year":"2006","journal-title":"J. Immunol."},{"key":"2025032405151171400_r51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.4049\/jimmunol.168.1.13","article-title":"Low-affinity anti-Smith antigen B cells are regulated by anergy as opposed to developmental arrest or differentiation to B-1","volume":"168","author":"Borrero","year":"2002","journal-title":"J. Immunol."},{"key":"2025032405151171400_r52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4049\/jimmunol.175.1.37","article-title":"Low-affinity, Smith antigen-specific B cells are tolerized by dendritic cells and macrophages","volume":"175","author":"Kilmon","year":"2005","journal-title":"J. Immunol."},{"key":"2025032405151171400_r53","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.4049\/jimmunol.177.4.2234","article-title":"Impaired intracellular calcium mobilization and NFATc1 availability in tolerant anti-insulin B cells","volume":"177","author":"Acevedo-Su\u00e1rez","year":"2006","journal-title":"J. Immunol."},{"key":"2025032405151171400_r54","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1089\/aid.2006.22.998","article-title":"Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies","volume":"22","author":"S\u00e1nchez-Mart\u00ednez","year":"2006","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"2025032405151171400_r55","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1097\/QAD.0b013e3282a4a632","article-title":"Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity","volume":"21","author":"Scherer","year":"2007","journal-title":"AIDS"},{"key":"2025032405151171400_r56","doi-asserted-by":"crossref","first-page":"20234","DOI":"10.1073\/pnas.0908713106","article-title":"Role of HIV membrane in neutralization by two broadly neutralizing antibodies","volume":"106","author":"Alam","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025032405151171400_r57","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S1074-7613(01)00251-5","article-title":"Editors and editing of anti-DNA receptors","volume":"15","author":"Li","year":"2001","journal-title":"Immunity"},{"key":"2025032405151171400_r58","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1074-7613(01)00131-5","article-title":"Negative selection at the pre-BCR checkpoint elicited by human mu heavy chains with unusual CDR3 regions","volume":"14","author":"Minegishi","year":"2001","journal-title":"Immunity"},{"key":"2025032405151171400_r59","doi-asserted-by":"crossref","first-page":"7773","DOI":"10.4049\/jimmunol.174.12.7773","article-title":"Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors","volume":"174","author":"Ivanov","year":"2005","journal-title":"J. Immunol."},{"key":"2025032405151171400_r60","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.4049\/jimmunol.171.9.4663","article-title":"Selection of Ig mu heavy chains by complementarity-determining region 3 length and amino acid composition","volume":"171","author":"Martin","year":"2003","journal-title":"J. Immunol."},{"key":"2025032405151171400_r61","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.4049\/jimmunol.167.3.1254","article-title":"A VH12 transgenic mouse exhibits defects in pre-B cell development and is unable to make IgM+ B cells","volume":"167","author":"Wang","year":"2001","journal-title":"J. Immunol."},{"key":"2025032405151171400_r62","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/ni.1794","article-title":"Checkpoints in lymphocyte development and autoimmune disease","volume":"11","author":"von Boehmer","year":"2010","journal-title":"Nat. Immunol."},{"key":"2025032405151171400_r63","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.it.2010.02.004","article-title":"The pre-B cell receptor: turning autoreactivity into self-defense","volume":"31","author":"Vettermann","year":"2010","journal-title":"Trends Immunol."},{"key":"2025032405151171400_r64","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.coi.2012.02.004","article-title":"Self-recognition and clonal selection: autoreactivity drives the generation of B cells","volume":"24","author":"Herzog","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"2025032405151171400_r65","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","article-title":"Broad and potent neutralization of HIV-1 by a gp41-specific human antibody","volume":"491","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"2025032405151171400_r66","doi-asserted-by":"crossref","first-page":"11725","DOI":"10.1128\/JVI.05680-11","article-title":"Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation","volume":"85","author":"Alam","year":"2011","journal-title":"J. Virol."},{"key":"2025032405151171400_r67","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.4049\/jimmunol.1202165","article-title":"Anti-HIV B Cell lines as candidate vaccine biosensors","volume":"189","author":"Ota","year":"2012","journal-title":"J. Immunol."},{"key":"2025032405151171400_r68","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1126\/science.1218692","article-title":"AID-driven deletion causes immunoglobulin heavy chain locus suicide recombination in B cells","volume":"336","author":"P\u00e9ron","year":"2012","journal-title":"Science"},{"key":"2025032405151171400_r69","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/art.30230","article-title":"Activation-induced deaminase-deficient MRL\/lpr mice secrete high levels of protective antibodies against lupus nephritis","volume":"63","author":"Jiang","year":"2011","journal-title":"Arthritis Rheum."},{"key":"2025032405151171400_r70","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1074-7613(03)00170-5","article-title":"Contribution of Vh gene replacement to the primary B cell repertoire","volume":"19","author":"Zhang","year":"2003","journal-title":"Immunity"}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/191\/3\/1260\/62511887\/1300770.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/191\/3\/1260\/62511887\/1300770.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:41:14Z","timestamp":1742863274000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/191\/3\/1260\/7991248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,1]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,8,1]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1300770","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,8]]},"published":{"date-parts":[[2013,8,1]]}}}